


Bamlanivimab Outpatient Scheduling and Medication Administration Procedures

Patient Selection and Scheduling Workflow

- **Providers** will enter patient into the statewide random allocation system (i.e. Lottery) for monoclonal antibody medications.
- **Scheduling:** If a patient is selected by the random allocation system, an email with these results documenting selection will be sent to the desired OIC location (North, South, Metro regions) scheduling groups.
 - Provider will place an order for the infusion (electronic therapy plan order in Epic, as per standard for other OIC infusions, or fax order using paper order form.
Note: Faxed orders will not be accepted at Anschutz campus infusion site.
 - Infusion center scheduler will contact patient as soon as possible to arrange infusion appointment within 10 days from symptom onset.
 - If a patient is past 10 days from symptom onset, they may not be scheduled for infusion. Refer the patient back to their primary care provider for ongoing care.
 - Confirm patient selection for Bamlanivimab infusion by the Colorado Department of Public Health and Environment (CDPHE) Random Allocation System via email receipt.
 - If no email confirmation for patient, please contact prescriber to confirm entry and selection by the CDPHE random allocation system. Patients should not be scheduled without documentation of selection through the CDPHE system.



Day of Infusion Procedures – RN Instructions

1. Patient arrives at infusion location and must wear a surgical mask (not cloth mask) during the entire time inside the facility.
2. Upon check-in:
 - a. Confirm patient identifiers (name, DOB).
 - b. Confirm that patient is on email list from random allocation selection.Provide patient with a surgical mask if they do not already have one.
3. Room the patient. The patient may not have anyone accompany them during the appointment. If they were dropped off by someone, their companion should leave the facility and return to pick them up after their appointment, in about 3 hours.
4. Perform and record vital signs, including baseline SpO₂.
 - a. If SpO₂ < 90% or patient has unstable vital signs, do not proceed with Bamlanivimab infusion and refer to local protocols for management (e.g. send patient to ED).
 - b. If vital signs are stable and SpO₂ ≥ 90%, proceed with orders to place PIV (or access existing line), request Bamlanivimab from pharmacy.
5. Infuse Bamlanivimab over 1 hour.
6. Repeat and record vital signs after medication completed.
7. Observe for 1 hour after end of infusion.
8. Refer to unit hypersensitivity/anaphylaxis protocol in the event of a hypersensitivity reaction.
9. Repeat and record vital signs at end of observation period and before patient discharge.
Patient may leave following observation period if stable and medication is tolerated.
10. Remove PIV or de-access indwelling line prior to discharge. Instruct patient to follow-up with primary care / ordering provider within 1-2 weeks, or sooner as needed.
11. Upon discharge, direct the patient to exit the facility, return to their vehicle, and depart immediately. Patient may not linger in the facility or visit other facility locations (e.g., pharmacy, cafeteria, etc.), and should return to their home isolation procedures.
12. Immediately report any side effects reported by the patient to RL Solutions or FDA MedWatch, per the requirement of the FDA Emergency Use Authorization.